| Mr Loi M Chang-stroman, MD | |
|
77-311 Sunset Dr, Kailua Kona, HI 96740-9754 | |
| (808) 329-6355 | |
| (808) 326-1549 |
| Full Name | Mr Loi M Chang-stroman |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 37 Years |
| Location | 77-311 Sunset Dr, Kailua Kona, Hawaii |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780770529 | NPI | - | NPPES |
| B90031 | Other | HMSA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 8269 (Hawaii) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Joy A Mcelroy M D Inc | 5698744936 | 3 |
News Archive
A new study uses a creative structure-based remodeling strategy to design a therapeutic protein that exhibits significant advantages over currently available treatments for a rare disease that often leads to cardiac and renal failure. The research, published by Cell Press on October 22nd in the American Journal of Human Genetics, describes a new and highly promising candidate for enzyme replacement therapy (ERT) for Fabry disease.
Waters Corporation (NYSE: WAT) today exhibited for the first time in Europe the Waters((R)) SYNAPT(TM) G2 a system offering scientists greater power, versatility and speed at the 18(th) International Mass Spectrometry Conference (IMSC). Rounding out its display of mass spectrometry (MS) and UltraPerformance Liquid Chromatography (UPLC((R)))/MS systems at IMSC will be Waters Xevo(TM) family of tandem quadrupole and time-of-flight mass spectrometers noted for their ease-of-use and versatility.
With a hard deadline looming, talks to prevent a government shutdown have been stymied for a week because Tea Party members of the House have demanded everything: not just some of their cuts but almost all of them, and not just a reduction in spending but a reduction only in the programs they don't like. Many are insisting Democrats also agree to nonbudgetary riders, like ending the financing of Planned Parenthood or health care reform.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Outpatient Surgery Center of Jonesboro has selected its ProVation® MD software for procedure documentation and coding. The software will be used to document Gastroenterological (GI) procedures at the facility.
› Verified 3 days ago
| Entity Name | Joy A Mcelroy M D Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770610875 PECOS PAC ID: 5698744936 Enrollment ID: O20041001001066 |
News Archive
A new study uses a creative structure-based remodeling strategy to design a therapeutic protein that exhibits significant advantages over currently available treatments for a rare disease that often leads to cardiac and renal failure. The research, published by Cell Press on October 22nd in the American Journal of Human Genetics, describes a new and highly promising candidate for enzyme replacement therapy (ERT) for Fabry disease.
Waters Corporation (NYSE: WAT) today exhibited for the first time in Europe the Waters((R)) SYNAPT(TM) G2 a system offering scientists greater power, versatility and speed at the 18(th) International Mass Spectrometry Conference (IMSC). Rounding out its display of mass spectrometry (MS) and UltraPerformance Liquid Chromatography (UPLC((R)))/MS systems at IMSC will be Waters Xevo(TM) family of tandem quadrupole and time-of-flight mass spectrometers noted for their ease-of-use and versatility.
With a hard deadline looming, talks to prevent a government shutdown have been stymied for a week because Tea Party members of the House have demanded everything: not just some of their cuts but almost all of them, and not just a reduction in spending but a reduction only in the programs they don't like. Many are insisting Democrats also agree to nonbudgetary riders, like ending the financing of Planned Parenthood or health care reform.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Outpatient Surgery Center of Jonesboro has selected its ProVation® MD software for procedure documentation and coding. The software will be used to document Gastroenterological (GI) procedures at the facility.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Loi M Chang-stroman, MD Po Box 2508, Kailua-kona, HI 96745-2508 Ph: (808) 329-6355 | Mr Loi M Chang-stroman, MD 77-311 Sunset Dr, Kailua Kona, HI 96740-9754 Ph: (808) 329-6355 |
News Archive
A new study uses a creative structure-based remodeling strategy to design a therapeutic protein that exhibits significant advantages over currently available treatments for a rare disease that often leads to cardiac and renal failure. The research, published by Cell Press on October 22nd in the American Journal of Human Genetics, describes a new and highly promising candidate for enzyme replacement therapy (ERT) for Fabry disease.
Waters Corporation (NYSE: WAT) today exhibited for the first time in Europe the Waters((R)) SYNAPT(TM) G2 a system offering scientists greater power, versatility and speed at the 18(th) International Mass Spectrometry Conference (IMSC). Rounding out its display of mass spectrometry (MS) and UltraPerformance Liquid Chromatography (UPLC((R)))/MS systems at IMSC will be Waters Xevo(TM) family of tandem quadrupole and time-of-flight mass spectrometers noted for their ease-of-use and versatility.
With a hard deadline looming, talks to prevent a government shutdown have been stymied for a week because Tea Party members of the House have demanded everything: not just some of their cuts but almost all of them, and not just a reduction in spending but a reduction only in the programs they don't like. Many are insisting Democrats also agree to nonbudgetary riders, like ending the financing of Planned Parenthood or health care reform.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Outpatient Surgery Center of Jonesboro has selected its ProVation® MD software for procedure documentation and coding. The software will be used to document Gastroenterological (GI) procedures at the facility.
› Verified 3 days ago
Dr. Clayton Lee Foster, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 78-6831 Alii Dr Ste 422, Kailua Kona, HI 96740 Phone: 808-747-8321 Fax: 808-322-6005 | |
Dr. Carrie L. Colmenares Roys, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 74-517 Honokohau St, Kailua Kona, HI 96740 Phone: 808-334-4400 | |
Kenneth Mark Riff, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 75-169 Hualalai Rd Ste 301, Kailua Kona, HI 96740 Phone: 808-329-2114 | |
Dr. Jeffrey Aric Bergsman, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 75-5995 Kuakini Hwy, Kailua Kona, HI 96740 Phone: 808-329-0774 Fax: 808-329-0776 | |
Dr. Navaid Asad, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 74-517 Honokohau St, Kailua Kona, HI 96740 Phone: 808-334-4400 | |
Toby Lee Smith, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 73-4603 Kaloko Loa Pl, Kailua Kona, HI 96740 Phone: 808-489-4731 | |
Dr. Wei Boon Ooi, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 75-184 Hualalai Rd Ste 202, Kailua Kona, HI 96740 Phone: 808-329-8251 Fax: 808-334-0130 |